Combination of mTOR inhibitor PP242 and AMPK activator metformin exerts enhanced inhibitory effects on colorectal carcinoma cells in vitro by blocking multiple kinase pathways.
Sign Up to like & getrecommendations! Published in 2022 at "Journal of chemotherapy"
DOI: 10.1080/1120009x.2022.2091122
Abstract: The second-generation mammalian target of rapamycin (mTOR) inhibitor PP242 has demonstrated limited success in some rapamycin-insensitive tumours. We examined the therapeutic potential of combining PP242 with adenosine 50- monophosphate-activated protein kinase (AMPK) activator metformin, using… read more here.
Keywords: pp242; combination; kinase; ampk ... See more keywords
Impact on Autophagy and Ultraviolet B Induced Responses of Treatment with the MTOR Inhibitors Rapamycin, Everolimus, Torin 1, and pp242 in Human Keratinocytes
Sign Up to like & getrecommendations! Published in 2017 at "Oxidative Medicine and Cellular Longevity"
DOI: 10.1155/2017/5930639
Abstract: The mechanistic target of Rapamycin (MTOR) protein is a crucial signaling regulator in mammalian cells that is extensively involved in cellular biology. The function of MTOR signaling in keratinocytes remains unclear. In this study, we… read more here.
Keywords: mtor inhibitors; pp242; inhibitors rapamycin; mtor signaling ... See more keywords